2013;112:1439 44. 9. Pislaru SV, Hussain I, Pellikka PA, et al. Misconceptions, diagnostic chal- lenges and treatment opportunities in bioprosthetic valve thrombosis: les- sons from a case series. Eur J Cardiothorac Surg. 2015;47:725 32. catheter aortic valve replacement. JACC Cardiovasc Interv. 2015;8:728 39. 11. Jose J, Sulimov DS, El-Mawardy M, et al. Clinical bioprosthetic heart valve thrombosis after transcatheter aortic valve replacement: inci- dence, characteristics, and treatment outcomes. JACC Cardiovasc Interv. 2017;10:686 97. 12. Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical out- comes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv. 2015;8:e001779. 13. Chakravarty T, S ndergaard L, Friedman J, et al. Subclinical leaflet throm- bosis in surgical and transcatheter bioprosthetic aortic valves: an observa- tional study. Lancet. 2017;389:2383 92. 14. Gozdek M, Raffa GM, Suwalski P, et al. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgi- cal redo aortic valve replacement in patients with degenerated aortic valve CLINICAL STATEMENTS AND GUIDELINES bioprostheses: systematic review and meta-analysis. Eur J Cardiothorac Surg. 2018;53:495 504. 15. Takagi H, Hari Y, Kawai N, et al. Meta-analysis of transcatheter aortic valve implantation for bicuspid versus tricuspid aortic valves. J Cardiol. 2019;74:40 8. 16. Kaneko T, Aranki S, Javed Q, et al. Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old. J Thorac Cardiovasc Surg. 2014;147:117 26. 17. Petrescu I, Egbe AC, Ionescu F, et al. Long-term outcomes of anticoagula- tion for bioprosthetic valve thrombosis. J Am Coll Cardiol. 2020;75:857 66. 11.9. Prosthetic Valve Regurgitation 1. Dvir D, Bourguignon T, Otto CM, et al. Standardized definition of struc- tural valve degeneration for surgical and transcatheter bioprosthetic aortic valves. Circulation. 2018;137:388 99. 2. Zoghbi WA, Chambers JB, Dumesnil JG, et al. 